Services and Research Collaboration Agreement between CellResearch Corporation Pte Ltd and the University of Colorado School of Medicine CellResearch Corporation Pte Ltd has entered into a Services and Research Collaboration Agreement with the University of Colorado School Of Medicine and ClinImmune Labs. The Service and Research Collaboration Agreement has the objective of achieving US FDA approval for therapeutic products of umbilical cord lining membrane progenitor/stem cells. [CellResearch Corporation Pte Ltd] Press Release Lilly and Immunocore Announce Immunotherapy-Based Clinical Trial Collaboration in Melanoma Eli Lilly and Company and Immunocore Limited announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib and merestinib for the treatment of melanoma. [Eli Lilly and Company] Press Release Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the patient enrollment for the pivotal Phase III CONCERTO trial has been finalized, as well as a planned sample size re-assessment analysis of the study. [Teva Pharmaceutical Industries Ltd.] Press Release In-Man Trials of Manufactured Blood within Two Years Lab produced red blood cells are set to be transfused into humans by 2017, NHS Blood and Transplant announced. The in-man clinical trials of manufactured blood form a key part of the blood and organ service’s 2020 Research and Development program. [NHS Blood and Transplant] Press Release Hans Clevers Awarded McEwen Award for Innovation at ISSCR 2015 The International Society for Stem Cell Research (ISSCR) has presented EuroStemCell partner, Hans Clevers, with the McEwen Award for Innovation at the opening of its annual meeting. [EuroStemCell] Press Release Celladon Corporation Provides Business Update Celladon Corporation confirmed its plans to suspend further research or development of its MYDICAR (AAV1/SERCA2a) program and its other pre-clinical programs including the Stem Cell Factor gene therapy and SERCA2b small molecule programs. [Celladon Corporation] Press Release CellResearch Corporation Receives New US Patent Approval for Exclusive Stem Cell Technology Amidst New Partnerships CellResearch Corporation Pte Ltd has received approval for its latest patent from the US Patent and Trademark Office. [CellResearch Corporation Pte Ltd] Press Release RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered Private Placement RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced it has completed its financing announced on June 1, 2015 [RepliCel Life Sciences Inc.] Press Release New CIRM-Funded Stem Cell Clinic at City of Hope Treats Its First Patient A City of Hope brain tumor patient was the first to be treated by City of Hope’s Alpha Clinic for Cell Therapy and Innovation, part of the state’s Alpha Clinics network, created to speed the development and delivery of stem cell therapies to patients who desperately need them. [City of Hope (Business Wire)] Press Release TxCell Announces a Temporary Partial Hold of Activities at Its Pilot Manufacturing Unit TxCell SA, a biotechnology company developing personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announced that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold. [TxCell SA] Press Release |